After the performance of last year, the Chinese antigen reagent company Jiu'an Medical's revenue in the first quarter of this year both fell sharply.In the first quarter, revenue was 1.495 billion yuan (RMB, the same below, about S $ 289 million), a year -on -year decrease of 93.12%, and a net profit of 601 million yuan, a decrease of 95.8%year -on -year.Jiu'an Medical said that the decline in revenue was mainly caused by the decline in the sales of the box during the reporting period.
According to the surging news report, Tianjin Jiu'an Medical Electronics Co., Ltd. released the 2022 financial report on Friday (April 28), and achieved revenue of 26.315 billion yuan during the period, an increase of 997.8%year -on -year;The company's shareholders' net profit was 16.03 billion yuan, an increase of 1664.19%year -on -year; net profit attributable to shareholders of listed companies was 16.358 billion yuan, an increase of 1888.82%year -on -year.
In the first to third quarter of 2022, the growth rate of Jiu'an medical revenue was 6646.79%, 519.77%, and 497.31%, respectively, and the net profit growth rate of returning to the mother was 37527.35%, 5465.51%, and 17452.26%.By the fourth quarter, the company's revenue growth rate fell to 7.43%alone, and the net profit of the mother -in -law changed from profit to 2012.78 million yuan, a year -on -year decrease of 102.34%.?????
In the first quarter of 2023, the performance of Jiu'an Medical continued the situation in the fourth quarter of last year, and both revenue and net profit fell.The financial report shows that in the first quarter, Jiu'an Medical achieved revenue of 1.495 billion yuan, a year -on -year decrease of 93.12%, and net profit was 601 million yuan, a year -on -year decrease of 95.8%; deduction of non -net profit was 353 million yuan, a year -on -year decrease of 97.54%.Jiu'an Medical said that the decline in revenue was mainly caused by the decline in the sales of the kit during the reporting period.
The performance of 2022 has increased greatly. In the financial report, Jiu'an Medical stated that the sales revenue of the IHEALTH kit of the Crown Diseases has increased significantly, which has increased the operating income of the iHealth series products (including kits).Last year's performance increased significantly.
IHEALTH series products are the pillar of revenue of Jiu'an Medical. During the reporting period, its revenue increased significantly to 25.969 billion yuan, an increase of 1296.27%year -on -year, and the gross profit margin reached 80.32%, accounting for 98.68%of revenue.
In terms of divided regions, foreign markets are the main source of revenue of Jiu'an Medical. During the period, revenue achieved revenue of 25.873 billion yuan, an increase of 1091.23%year -on -year, accounting for 98.32%of total revenue.
The financial report states that due to the influence of the development of the American epidemic, the demand for the product of the kit has increased significantly.Due to the strict US FDA access, when Jiu'an Medical was certified, there were only 9 crown disease antigen kit providers in the US market. Compared with the European market, it was less competitive.The volume is soaring.
